We can't find the internet
Attempting to reconnect
25770.2 PFLS-LS
25770.2 PFLS-LS
Zusammenfassung
Development of a proprietary biomarker based companion diagnostic for identification and selection of cancer patients with disease driven by Notch pathway activation to be selected for treatment with Cellestia`s first-in-class pan NOTCH inhibitor and clinical development candidate drug CB-103.
Weitere Texte
Abstract
Development of a proprietary biomarker based companion diagnostic for identification and selection of cancer patients with disease driven by NOTCH pathway activation, for treatment with Cellestia`s first-in-class pan NOTCH inhibitor and clinical development candidate drug CB-103.
Beteiligte
Rajwinder Lehal
Wirtschaftspartner
raj.lehal@cellestia.com
Cellestia Biotech AG CHE-162.364.457 Rajwinder Lehal Hochbergerstr. 60C 4057 Basel BS CH
Freddy Radtke
Kontaktperson
freddy.radtke@epfl.ch
EPFL SV ISREC UPRAD Life Science Faculty Freddy Radtke Station 19 1015 Lausanne VD CH
Projektdetails
- Forschungsstelle
- INNOSUISSE
- Projektstatus
- Abgeschlossen
- Projekttyp
- Forschungsprojekt
- Startdatum
- 2017-09-30
- Enddatum
- 2019-09-30
- Bewilligte Gesamtkosten
- CHF 654452.35
- Sektion
- 20 Förderbereich Life Sciences
- NABS Politikbereich
- Industrielle Produktivität und Technologie
Forschungsdisziplinen
- T490 Biotechnology 100.0%